Showing posts with label stem cell autism treatment. Show all posts
Showing posts with label stem cell autism treatment. Show all posts

Wednesday, April 14, 2010

Autism and Experimental Stem Cell Treatment

Attached is part of a PR Web Press Release for a clinical trial application being submitted to Greek authorities by AdiStem Tehcnology. It indicates thatgroup of doctors in Greece are preparing a protocol for submission to the Greek Ministry of Health for an official clinical trial of stem cell treatment on children with autism spectrum disorders:

The stem cell technology developed by AdiStem for the past 5 years has been used and trialed by doctors around the world for the treatment of type II diabetes and its complications, osteoarthritis, and cosmetic medicine. Physicians in Greece approached the company recently with the intent to treat Yannis, the son of Dr. Solomos, a cardiologist. Yannis, a 9 year old boy, had been diagnosed with autism but not responded to standard treatments.

An experienced doctor, the father, Dr Solomos, carefully reviewed the case studies of other children with Autism who had received the AdiStem stem cell treatment in Europe and Asia, and was convinced of its safety and potential for improving the condition of his son. With the help of experienced pediatric surgeons Yannis underwent an hour long mini-liposuction procedure at Kratiko Nikaias Hospital in Athens in which 200cc of abdominal fat was harvested. The fat was dissolved, the stem cells isolated and then activated, and over 100 million cells were returned to Yannis through a standard intravenous drip. Yannis was discharged on the same day.

Just one month later, his father was astonished to hear Yannis talking to him on the phone for the first time. Dr. Solomos explained: "my boy has simply not been able to speak to me on the phone before". Asked if he’d noticed any other changes, he replied: "His school tells me his attention has improved. We experience him nearer to us and he feels us. I see a change in his ability to connect with other children. He plays with them now, which he used to avoid. He has also become more interested in letters and numbers". (This interview with Dr.Solomos was recorded on video and can be viewed at "www.adistem.com/application/autism.htm").

Present during the treatment, Dr. Koliakos, Associate Professor at Aristotle University and President of Hellenic Research Foundation Stem Cell Bank pointed out: "One month after the therapy Yannis has shown remarkable progress according to his father's observations. The child will be reevaluated by pediatric psychiatrists 3 months after the therapy to measure the extent of progress in his condition and to decide if the remainder of his stem cells, presently stored in liquid nitrogen, should be administered".

Dr.Kolaikos continued: "We're convinced about the safety of intravenous adipose stem cell therapy – if supported by accredited facilities – and our team has now applied for a large formal clinical trial on autism using AdiStem's stem cell protocol here in Greece".

Terry Grossman, M.D., stem cell researcher from Golden, Colorado said, "I was present to observe 9 year old Yannis undergo the stem cell procedure at the Kratiko Nikaias Hospital in Athens. Further studies are needed, but it is possible that stem cell therapy will soon be available as a powerful new tool to help children with autistic spectrum disorders."

There is much controversy surrounding most aspects of autism spectrum disorders including issues concerning treatment and research involving children.  In this case the PR Web press release states that a trial was run with a child whose father, an experienced medical doctor, consented to his participation  after reviewing case studies involving other children with autism who had received the treatment.  The father, a medical doctor, also provide his observations which indicated substantial improvement in his son's condition.  The procedure was performed by experienced pediatric surgeons and   is vouched for by a Greek professor and researcher as being safe when administered at a proper facility. In addition to the father's observations the child will be seen at follow ups by pediatric psychiatrists for further measurement of his progress and for a determination of whether to continue with the treatment.

The procedure itself was observed by an American stem cell researcher/doctor who says further study is needed but that  but it is possible that stem cell therapy will soon be available as a powerful new tool to help children with autistic spectrum disorders.  The research team involved has applied for a large formal clinical trial on autism using AdiStem's stem cell protocol.

It will be interesting to see what comes of the Adistem application and formal clinical trial results.   This father of a severely autistic 14 year old boy has insisted that my son receive only evidence based interventions and I will not depart from that principle.  But I do not close my mind to new interventions either if they are subsequently supported by a strong evidence base.  If  responsible studies  conducted safely, produce credible results and provide reliable evidence of new interventions that could help my son then I would want, in consultation with trusted professional advisers, to consider new interventions for his benefit.   
It remains to be seen whether the AdiStem trials will provide such evidence but in the meantime this father of a severely autistic son will keep an open mind on the subject. 

Saturday, May 23, 2009

Autism Treatments: Will Experimental Stem Cell Treatment Help?

While the autism world buzzes over the Chicago Tribune's demolition of the Geiers and the Lupron treatment the need for evidence based treatments that might cure autism disorders remains unfulfilled and largely ignored by the medical research establishment. ABA is a solidly evidence based intervention which can help autistic children make substantial communication, intellectual, behavioral and adaptive skills gains. But the demand for a complete cure for autism disorders remains and as long as it does some parents will seek out non-evidence based treatments for their child's autism. Of course, treatments can not become evidence based unless experiments are undertaken. Hopefully, as in anything involving children, the best interests of the individual child involved will always be considered of primary importance.

13WHAM.com of Rochester reports that the parents of a Rochester, New York boy with autism are beginning their own autism "experiment" with stem cell treatment. WHAM.com reports that the Patterson family are taking their autistic son to Peru for stem cell treatment. The experimental treatment will cost $25,000. The Pattersons will be accompanied by Dr. Burton Feinerman:

"Dr. Burton Feinerman, a Mayo Clinic trained cellular therapy specialist, is working with the Pattersons. He has used the stem cell procedure on children who’ve had strokes, brain injuries and other neurological problems. "

WHAM.com reports that the Pattersons have been assured that the procedure is safe although they have been no guarantees of success. Hopefully the procedure is indeed safe for the Patterson boy. The presence of a Mayo Clinic trained cellular therapy specialist, with actual experience in stem cell procedures, during the treatment suggests that it will be. Hopefully too the necessary steps will be taken to ensure that, whatever the outcome for the boy involved the results will have some scientific value, will be of some use in assessing the merits of this particular form of autism treatment, whether those results show promise ... or not.




Bookmark and Share

Saturday, December 27, 2008

Possible Autism Treatment? Israeli Scientists Use Stem Cells To Reverse Learning Disorders In Mice

Israel21c reports that Israeli scientists have succeeded in using stem cells to revere learning deficits in the offspring of pregnant mice who were exposed to heroin and the pesticide organophosphate. The article by Israel21c staff speculates that the findings could ultimately lead to significant breakthroughs in treating learning disorders.

Researchers, including Prof. Joseph Yanai and Prof. Tamir Ben-Hur of the Hebrew University-Hadassah Medical School and Prof. Ted Slotkin at Duke University in North Carolina, used direct neural stem cell transportation into the brains of the affected mice offspring with marked results:

The recovery was almost 100 percent, as proved in behavioral tests in which the treated animals improved to normal behavior and learning scores after the transplantation. On the molecular level, brain chemistry of the treated animals was also restored to normal. ...... The scientists found that before they die the neural stem cells succeed in inducing the host brain to produce large numbers of stem cells which repair the damage. These findings, which answered a major question in the stem cell research community, were published earlier this year in the leading journal, Molecular Psychiatry.

The abstract for the article can be viewed, and the article purchased at Molecular Psychiatry. The citation for the article is Molecular Psychiatry (2008) 13, 222–231; doi:10.1038/sj.mp.4002084; published online 18 September 2007.

Neither the Israel21c article nor the study abstract mention autism disorders specifically but they do refer to potential stem cell treatment generally of neural and behavioral birth defects and disorders.




Bookmark and Share

Wednesday, December 03, 2008

Autism and Stem Cell Tourists

In "Stem Cell Tourists" Go Abroad for Unproven Treatments National Geographic News reports on the growing numbers of Americans traveling abroad to seek stem cell treatment for a variety of conditions including Parkinson's, Diabetes, heart disease and emphysema. The NG article reports expert concerns about stem cell treatment being oversold as proven therapy rather than experimental, the risk of harmful complications and great expense for the patients. Although autism is not mentioned in the NG article Autism Spectrum Disorders are amongst conditions for which stem cell treatments are offered outside the United States and Canada.




Bookmark and Share

Wednesday, August 01, 2007

Autism Stem Cell Therapy Patent Application Filed









Medistem Laboratories Inc., the company whose researchers published the recent stem cell treatment proposal in the Journal of Translational Medicine has applied for a patent in respect of its stem cell therapy which covers patient selection, therapeutic combinations and various stem cell types. Hopefully the patent, if granted, promotes further research and development in this area, and if the treatment is proven effective and beneficial to autistic patients, does not render the price of treatment beyond reach for generations.


Medistem Announces Autism Stem Cell Therapy Paper and Filing of IP Aug 1 2007, 5:05 AM EST MARKETWIRE Aug 01, 2007 SCOTTSDALE, AZ MARKET WIRE Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) announced today the filing of IP and publication of a peer reviewed paper describing a novel method of selecting specific subsets of autistic patients for treatment with a combination of cellular therapies. "Based on positive case report data from one of our licensees, Medistem plans to explore the possibility of seeking regulatory approval in the U.S. for a Phase I clinical trial involving our novel stem cell therapeutic methods for treatment of autism," said Neil Riordan PhD, President and CEO of Medistem. He continued, "We are at the stage where a patent application has been filed, we've announced the scientific basis for our program in a peer reviewed journal, and now we are seeking and initiating discussions with clinical collaborators and patient interest groups in the U.S." Medistem published a paper entitled "Stem Cell Therapy for Autism" in the Journal of Translational Medicine that is freely available online at http://www.translational-medicine.com/content/pdf/1479-5876-5-30.pdf. A video summary of the paper may be seen at http://www.youtube.com/watch?v=FlSaXCzLW6w Thomas Ichim, Medistem's Chief of Scientific Development and primary author on the paper, stated, "Given the staggering incidence of autism in the U.S. (approximately 1 in 166), and the lack of viable treatment options, we believe that our IP in this area will not only allow for internal product development, but also enable Medistem to seek collaboration with other companies that have approval for using stem cells in the U.S. under clinical trial exemptions." Medistem has numerous patent applications filed in the area of stem cell expansion, composition of matter, and therapeutic use. The patent application entitled "Stem Cell Therapy for Autism" covers patient selection, therapeutic combinations, and various stem cell types for the treatment of autism. About Medistem Laboratories, Inc. Medistem Laboratories is a biotechnology company that discovers, develops, and commercializes adult stem cell products that address serious medical conditions. While drug discovery and development is its primary focus, Medistem has compiled a body of proprietary technologies it outlicenses to commercial entities in markets where stem cell administration is permissible. Due to its licensee relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products. Cautionary Statement This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs. These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission. Contact: Medistem Laboratories, Inc. Chris McGuinn 602-318-3535 http://www.medisteminc.com
http://www.genengnews.com/news/bnitem.aspx?name=21104666 SOURCE: Medistem Laboratories

Saturday, July 28, 2007

Stem Cell Autism Treatment Proposal















More fascinating developments in autism research are brought forward with publication of a peer reviewed open access article in the Journal of Translational Medicine 2007, 5:30. The authors propose the use of stem cells to treat autism. Translation Medicine refers to a field of medicine which attempts to convert research into actual treatment for patients, a joining of research and clinical practice of medicine. The proposal is premised on a consistent association of autism with immune abnormalities and neural hypoperfusion (decreased blood flow). The authors speculate that stem cells might be used to stimulate repair of neural damage.

Four of the authors are associated with the Institute of Cellular Medicine which indicates that it is now accepting some autistic patients for stem cell therapy:

Stem Cell Therapy is Available Now The Institute of Cellular Medicine (ICM) is currently accepting patients with the following conditions for stem cell therapy:


  • ALS
  • Autism
  • Autoimmune Diseases
  • Cardiovascular Disease

  • Cerebral Palsy
  • Diabetes Type 2
  • Multiple Sclerosis


  • Parkinson's Disease
  • Rheumatoid Arthritis
  • Stroke

  • http://www.cellmedicine.com/

    Stem Cell Therapy for Autism Thomas E Ichim1 , Fabio Solano2 , Eduardo Glenn2 , Frank Morales2 , Leonard Smith2 , George Zabrecky3 and Neil H Riordan1 ,4 1Medistem Laboratories Inc, Tempe, Arizona, USA 2Institute for Cellular Medicine, San Jose, Costa Rica 3Americas Medical Center, Ridgefield, Connecticut, USA 42027 E. Cedar Street Suite 102 Tempe, AZ 85281, USA
    Journal of Translational Medicine 2007, 5:30 doi:10.1186/1479-5876-5-30

    Autistic disorder, or autism is the most common form of ASD. Although several neurophysiological alterations have been associated with autism, immune abnormalities and neural hypoperfusion appear to be broadly consistent. These appear to be causative since correlation of altered inflammatory responses, and hypoperfusion with symptology is reported. Mesenchymal stem cells (MSC) are in late phases of clinical development for treatment of graft versus host disease and Crohn's Disease, two conditions of immune dysregulation. Cord blood CD34+ cells are known to be potent angiogenic stimulators, having demonstrated positive effects in not only peripheral ischemia, but also in models of cerebral ischemia. Additionally, anecdotal clinical cases have reported responses in autistic children receiving cord blood CD34+ cells. We propose the combined use of MSC and cord blood CD34+cells may be useful in the treatment of autism.

    http://www.translational-medicine.com/content/5/1/30

    http://www.translational-medicine.com/content/pdf/1479-5876-5-30.pdf